Form 8-K Filing: Officer and Director Change

HeartSciences Inc. reported the passing of its Chief Operating Officer, Corporate Secretary, and Board Member, Mark Hilz, on April 1, 2026. Mr. Hilz, aged 67, had been with the company since 2013 and held his officer positions since March 2022. The company expressed condolences to his family and stated that due to the recent launch of its MyoVista Insights™ software platform and the submission of the MyoVista® wavECG™ device for FDA clearance, it does not anticipate hiring a replacement COO or making changes to its business operations or commercialization plans as a result of Mr. Hilz's passing. The FDA submission was originally made in December 2025 for 510(k) premarket clearance. Andrew Simpson, President, CEO, and Chairman of the Board, signed the report on April 3, 2026.